-
The market of traditional Chinese medicine formula granules will be further expanded, and pharmaceutical companies are rushing to the beach
Time of Update: 2022-03-06
Among them, on February 8, 2022, Jilin Aodong issued an announcement stating that Yanbian Pharmaceutical, a holding subsidiary, received 8 national standard "Chinese Medicine Formula Granules Listing Recording Certificates", including Angelica Formula Granules, Jiu Danshen Formula Granules, etc.
-
Beilu Pharmaceutical's iopamidol injection passed the consistency evaluation of generic drugs
Time of Update: 2022-03-06
On February 16, Beilu Pharmaceutical announced that it had recently received the “Approval Notice for Supplementary Drug Application” (Notice No.
: 2022B00641, 2022B00642) issued by the State Drug Administration for two specifications of iopamidol injection.
Drugs pass the quality and efficacy consistency evaluation of generic drugs .
-
Xinlitai SAL0114 Tablets Obtained Clinical Trial Approval Notice
Time of Update: 2022-03-06
On February 16, Xinlitai issued an announcement stating that the company received the "Clinical Trial Approval Notice" approved and issued by the State Drug Administration, and agreed to carry out clinical trials of SAL0114 tablets .
-
A large number of pharmaceutical companies will use acquisitions to accelerate the pace of innovation in the future
Time of Update: 2022-03-06
Of course, regarding CSPC's investment in the acquisition of a Biotech company, some insiders believe that this is actually a microcosm of how domestic traditional big pharmaceutical companies will accelerate the pace of innovation through acquisitions .
According to public information, Yongtai Bio is an innovative biotechnology company engaged in the research and development of cellular immunotherapy products.
-
The prosperity of the domestic CXO industry will continue, but it still faces two major challenges
Time of Update: 2022-03-06
In recent years, the global innovative drug industry has developed rapidly, but new drug R&D has the characteristics of high risk, high investment, and long return period.
-
As long as it is domestically produced, the results of the 21 million device purchase order will be announced (with a list attached)
Time of Update: 2022-03-06
According to information disclosed by Lingang, the initial investment of the Medtronic Lingang project is about 300 million yuan, which will be used for the research and development and industrialization of cardiovascular disease-related products .
-
Centralized procurement attacks pharmaceutical companies in all directions to survive in this way
Time of Update: 2022-03-06
Of course, the hospital can also do both Those who are not guilty, kick them all out, and then enter one back through channels such as the Pharmacy Council;For question 3, in the case of multiple companies being selected, after completing the agreed purchase volume, some provinces may differentiate the preferred products based on price, quality level, A and B categories, etc.
-
The growth rate of the centrifuge market exceeds 23%, and the biomedical industry is a major "support force" behind it
Time of Update: 2022-03-06
Some medical centrifuge manufacturers said that facing the future, the company will continue to increase investment in research and development, attach importance to innovation, continuously improve the stability and quality of domestic centrifuges, seize the opportunity of import substitution, and help the pharmaceutical and other industries to develop with higher quality .
-
The policy of Chinese herbal medicines in one place is relaxed, and pharmacies can be exempted from fines of 100,000 yuan
Time of Update: 2022-03-06
The policy of Chinese herbal decoction pieces is relaxed, and pharmacies can be exempted from fines of 100,000 A few days ago, the Jiangsu Food and Drug Administration issued the "Guiding Opinions on the Determination of Jiangsu Province Traditional Chinese Medicine Pieces Do Not Comply with Drug Standards and Does Not Affect Safety and Effectiveness (Trial)" (hereinafter referred to as "Opinions") .
-
The personnel of the pharmaceutical company changed, and another deputy general manager resigned
Time of Update: 2022-03-06
Fuxiang Pharmaceutical recently announced that the company's board of directors received a written resignation report from Huang Xiaodong, deputy general manager and board secretary on February 14, 2022.
-
Shanghai announces the list of the first batch of restricted pharmacy drugs to be purchased online in 2022
Time of Update: 2022-03-06
Drug Information Announcement On February 15, 2022, the drug information will be pushed to designated pharmacies through the "Shanghai Pharmaceutical Procurement Service and Supervision Information System" (hereinafter referred to as the Sunshine Platform), which will take effect on February 17, 2022 .
-
Industry: 2022 will become the "Year of Procurement of Traditional Chinese Medicine"
Time of Update: 2022-03-06
At the end of the same year, the “Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine” of the two departments clearly stated that it encouraged the inclusion of traditional Chinese medicine formula granules purchased by public medical institutions into the provincial centralized pharmaceutical procurement platform for online transactions to promote open and transparent transactions .
-
210 drug reviews!
Time of Update: 2022-03-06
According to the notice, 210 products were reviewed and purchased online, of which 122 pharmaceutical companies including Amoxicillin Capsules of Yuekang Pharmaceutical Group, Omeprazole Enteric-Coated Tablets of Fangsheng Pharmaceutical, Bicalutamide Tablets of Jianghaizheng Pharmaceutical, Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group 's products .
-
Regular withdrawal of drugs on the Internet has become the norm, and another batch of drugs has been withdrawn from the Internet
Time of Update: 2022-03-06
In fact, since last year, Shanghai has issued a number of online purchase notices, and 18 drugs have been closed for purchase because medical institutions have not completed the negotiation and acceptance .
-
In Q3 2021, the sales of two blockbuster monoclonal antibodies exceeded 5 billion yuan
Time of Update: 2022-03-06
However, from the perspective of the market structure, the current domestic bevacizumab injection market is mainly divided by the original researcher Roche and Qilu Pharmaceutical .
. However, with the entry of domestic pharmaceutical companies, the industry expects that the Roche bevacizumab injection market will be impacted in the future.
-
The 2022 performance of the chain pharmacy giant will usher in an upward turning point!
Time of Update: 2022-03-06
In this regard, the industry predicts that with the continuous expansion of chain pharmacy giants, the industry concentration will continue to increase steadily in the future, and the outflow of prescriptions is expected to accelerate under the resonance of multiple factors.
-
Huang Xiaodong, Deputy General Manager and Secretary of the Board of Directors of Fuxiang Pharmaceutical, resigned
Time of Update: 2022-03-06
On the evening of February 14, Fuxiang Pharmaceutical announced that Huang Xiaodong resigned from the company's deputy general manager and board secretary due to personal reasons, and would no longer hold any positions in the company after his resignation .
-
Jitai Pharmaceutical Appoints Academician Chen Hongmin as President and Head of R&D of the US Company
Time of Update: 2022-03-06
Before joining Jitai, Academician Hongmin Chen served as the Chief Scientific Officer of Kala Pharmaceuticals, a biotech company he helped found in 2010 .
Before joining Kala Pharmaceuticals, Academician Hongmin Chen helped found TransForm Pharmaceuticals, which was acquired by Johnson & Johnson in 2005 .
-
The path for domestic innovative drugs to go overseas is clearer, and the industry is optimistic about these types of innovative drug companies
Time of Update: 2022-03-06
The agency believes that the ODAC meeting has clarified two new paths for domestic innovative drugs to go overseas in the future: first, the global multi-center clinical trial layout; second, targeting unmet clinical needs in Europe and the United States, or therapies with high scarcity .
-
Vancomycin Hydrochloride for Injection by Puli Pharmaceuticals obtained the marketing authorization of the Ministry of Health of Costa Rica
Time of Update: 2022-03-06
It is indicated for penicillin-allergic patients, patients who cannot receive or respond to other drugs (including penicillin or cephalosporins), and infections caused by vancomycin-sensitive organisms that are resistant to other antimicrobials .
